Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
GLP-1RA

Novo-Teva Generic Victoza Settled; Launch Date Rationale Unclear

Here is a brief preview of this blast: Novo Nordisk announced it has settled the patent dispute with Teva regarding Teva's ANDA filing for generic Victoza. Recall, in February 2017, Teva publicly disclosed the generic Victoza filing, and Novo subsequently announced their lawsuit in March 2017. According to the press release, Novo and Teva's settlement entitles Teva to launch generic Victoza as early as December 22, 2023 (without pediatric exclusivity) unless Novo's Victoza patents are invalidated or another generic Victoza is launched. Below, FENIX provides thoughts on the settlement with Teva as well as insight into the Victoza pediatric exclusivity extension.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.